Clinical trials: Breast
Neoplasms, Breast
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone…
- Trial name
- ALTTO (NCT00490139)
- Testing
- Lapatinib, Trastuzumab
- Where
- 924 sites in United States, Argentina and 42 more
- Volunteers
- 8,381 people
- Sponsor
- Novartis Pharmaceuticals
Quality of Life, Breast Cancer
Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers
Latina breast cancer survivors report lower quality of life (QOL) than non-Latina survivors. Lower QOL can lead to poorer functional and cancer-related survival outcomes.
- Trial name
- NCT02222337
- Testing
- Nueva Vida Intervention
- Where
- 4 sites in United States
- Volunteers
- 272 people
- Sponsor
- Georgetown University
Breast Cancer
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast cancer who are candidates for taxane-based…
- Trial name
- NCT00333775
- Testing
- Docetaxel, Bevacizumab
- Where
- 114 sites in Australia, Austria and 22 more
- Volunteers
- 736 people
- Sponsor
- Hoffmann-La Roche
HER2/Neu Positive, Progesterone Receptor Positive
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01275677
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 1,283 sites in United States, Canada and 2 more
- Volunteers
- 3,270 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
mHealth Behavioral Cancer Pain Intervention for Medically Underserved Patients
The efficacy of a mobile health (mHealth) behavioral cancer pain intervention designed to decrease pain and disability for breast cancer patients in medically underserved areas has not been investigated.
- Trial name
- ICAN-NC (NCT04175639)
- Testing
- Mobile Health Pain Coping Skills Training (mPCST)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Duke University
Breast Cancer
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth…
- Trial name
- NCT03084237
- Testing
- HLX02, Herceptin®, docetaxel
- Where
- 88 sites in China, Philippines and 1 more
- Volunteers
- 652 people
- Sponsor
- Shanghai Henlius Biotech
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
This phase I/II trial investigates the side effects of genetically engineered cells called FH-MagIC TCR-T cells and how well they work with atezolizumab in treating patients with triple negative breast cancer, urothelial cancer…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT04639245
- Testing
- Atezolizumab, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
Women with hormone-receptor positive breast cancer are typically treated with hormone therapy as part of their treatment after surgery.
- Trial name
- NCT00555477
- Testing
- anastrozole
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breastfeeding
Effects of Music Therapy on Breastfeeding Among Mothers of Premature Newborns
The purpose of this study is to evaluate the impact of music therapy on breastfeeding rates among mothers of premature newborns.
- Trial name
- NCT00930761
- Testing
- Music therapy
- Where
- Brazil
- Volunteers
- 101 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Breast Cancer
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499083
- Testing
- therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Estrogen Receptor Positive, Recurrent Breast Carcinoma
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted…
- Conditions
- Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT02149173
- Testing
- Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Breast Cancer
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and…
- Trial name
- NCT01937117
- Testing
- Positron emission tomography (PET), Trastuzumab, Pertuzumab
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00633750
- Testing
- erlotinib hydrochloride, TUNEL assay, protein expression analysis
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Non-small Cell Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
- Trial name
- NCT02308020
- Testing
- Abemaciclib
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Stage II Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT)
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- MARGOT (NCT04425018)
- Testing
- Paclitaxel, Pertuzumab, Margetuximab
- Where
- 14 sites in United States
- Volunteers
- 174 people
- Sponsor
- Dana-Farber Cancer Institute
Sexual Dysfunction, Physiological, Body Image
Women's Interventions for Sexual Health: WISH
The overall objective of this program of research is to improve sexual health outcomes for women diagnosed with breast cancer. Our team is developing a multi-component intervention for the four key predictors of sexual health in…
- Conditions
- Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
- Trial name
- WISH (NCT05692960)
- Testing
- Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Tennessee, Knoxville
Breast Cancer
A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers
In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical…
- Trial name
- NCT02550210
- Testing
- Breast Cancer Locator (BCL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression.
- Trial name
- NCT02291913
- Testing
- Everolimus, Exemestane, Tamoxifen
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Breast Cancer
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093808
- Testing
- trastuzumab, capecitabine, vinorelbine tartrate
- Where
- 147 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.